Browsing by Sponsor/Funder Myeloma UK
Showing results 1 to 2 of 2
| Issue Date | Title | Author(s) |
|---|---|---|
| 1-Oct-2021 | Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multi-centre, phase II, randomized, controlled trial (MUKfive) | Yong, KL; Hinsley, S; Auner, HW; Bygrave, C; Kaiser, MF, et al |
| 2-Oct-2020 | The MUK eight protocol: A randomised phase II trial of Cyclophosphamide and Dexamethasone in combination with Ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor | Hinsley, S; Walker, K; Sherratt, D; Bailey, L; Reed, S, et al |